Erick Morris Selected Research

S55746

1/2019	Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
4/2018	S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Erick Morris Research Topics

Disease

2	Leukemia 12/2020 - 01/2019
2	Neoplasms (Cancer) 04/2018 - 12/2016
1	Pneumonia (Pneumonitis) 01/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022
1	Nausea 01/2022
1	Fatigue 01/2022
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2020
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 04/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 04/2018
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 04/2018
1	Colorectal Neoplasms (Colorectal Cancer) 12/2016
1	Colonic Neoplasms (Colon Cancer) 10/2016

Drug/Important Bio-Agent (IBA)

2	S63845IBA 12/2020 - 01/2019
2	venetoclaxIBA 12/2020 - 04/2018
2	S55746IBA 01/2019 - 04/2018
1	Alanine (L-Alanine)FDA Link 01/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022
1	Adenosine (Adenocard)FDA LinkGeneric 01/2022
1	SteroidsIBA 01/2022
1	spartalizumabIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 12/2020
1	Apoptosis Regulatory ProteinsIBA 04/2018
1	Drug CombinationsIBA 12/2016
1	Pharmaceutical PreparationsIBA 12/2016
1	Indicators and Reagents (Reagents)IBA 10/2016

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2019 - 12/2016
1	Therapeutics 12/2016